Browse by author
Lookup NU author(s): Dr Rachael Raw
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2021 Elsevier LtdThe BNT162b2/Pfizer SARS-CoV-2 vaccine has been widely used in the UK, particularly amongst healthcare workers (HCWs). To establish whether previous COVID-19 influenced vaccine-associated Adverse Events (AEs), we conducted a survey-based study of HCWs in Northeast England. Out of 1238 HCWs, 32% self-reported prior positive PCR and/or antibody test for SARS-CoV-2. Post-dose AEs were worse in those with prior COVID-19 after the first, but not the second dose of vaccine. Second dose AEs were greater in frequency/severity, regardless of COVID-19 history, and they were more systemic in nature. Women and younger HCW were more likely to report AEs after both doses, while dosing interval had no effect on AEs. Ongoing Symptomatic COVID-19 was associated with greater frequency/severity of AEs after dose 2, but not dose one. Overall, AEs were self-limiting and short-lived (i.e.,<48 h) in nature. These findings have implications for vaccine hesitancy and informing guidelines for recommended dosing protocols.
Author(s): Raw RK, Rees J, Kelly CA, Wroe C, Chadwick DR
Publication type: Article
Publication status: Published
Journal: Vaccine
Year: 2022
Volume: 40
Issue: 3
Pages: 418-423
Print publication date: 24/01/2022
Online publication date: 04/12/2021
Acceptance date: 29/11/2021
ISSN (print): 0264-410X
ISSN (electronic): 1873-2518
Publisher: Elsevier Ltd
URL: https://doi.org/10.1016/j.vaccine.2021.11.090
DOI: 10.1016/j.vaccine.2021.11.090
Altmetrics provided by Altmetric